Last reviewed · How we verify
Macugen (pegaptanib)
Macugen (pegaptanib) is a small molecule drug that targets vascular endothelial growth factor A (VEGF-A), a protein involved in the growth of new blood vessels. It was originally developed by Valeant Pharms LLC and is now owned by Bausch and Lomb Inc. Macugen was FDA-approved in 2004 for the treatment of exudative age-related macular degeneration. The drug is off-patent, meaning it is no longer protected by patents, and there are currently no generic manufacturers. Macugen is used to slow the progression of vision loss in patients with this condition.
At a glance
| Generic name | pegaptanib |
|---|---|
| Sponsor | Bausch Health |
| Target | Vascular endothelial growth factor A |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 2004 |
Approved indications
- Exudative age-related macular degeneration
Common side effects
Key clinical trials
- Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema (NA)
- Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium (PHASE4)
- Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice
- A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
- A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension. (PHASE2,PHASE3)
- Neovascular Age-related Macular Degeneration
- Cohort Study of the Clinical Course of Macular Diseases in Kagawa (PHASE4)
- Cohort Study of the Clinical Course of Macular Diseases in Japanese
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Macugen CI brief — competitive landscape report
- Macugen updates RSS · CI watch RSS
- Bausch Health portfolio CI